Cytokinetics CYTK Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's total liabilities?
- Cytokinetics (CYTK) reported total liabilities of $2.1B in Q1 2026.
- How has Cytokinetics's total liabilities changed year-over-year?
- Cytokinetics's total liabilities increased by 37.2% year-over-year, from $1.53B to $2.1B.
- What is the long-term trend for Cytokinetics's total liabilities?
- Over 5 years (2020 to 2025), Cytokinetics's total liabilities has grown at a 37.7% compound annual growth rate (CAGR), from $420.42M to $2.08B.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and suppliers.
- How do you interpret total liabilities?
- Rising total liabilities relative to assets may signal increasing financial risk or reliance on debt to fund R&D.
- How does total liabilities compare across companies?
- Varies widely based on the company's stage of development and capital structure strategy.